Akron Children's Hospital > For Families & Patients > Research > Pediatric Clinical Studies > Open Clinical Studies

PBTC 039 - Peginterferon Alfa-2b in Treating Younger Patients With Craniopharyngioma That is Recurrent or Cannot Be Removed By Surgery

Peginterferon Alfa-2b in Treating Younger Patients With Craniopharyngioma

Description:

For complete information, please visit the study on clinicaltrials.gov

This study is being done in collaboration with Cincinnati Children's Hospital.

Interested in participating?

We are currently recruiting

Full IRB Study Title:

PBTC-039: Phase II Study of Peginterferon alfa-2b (PEGIntron) for Pediatric Patients with Un-resectable or Recurrent Craniopharyngioma - Cincinnati

IRB Study ID:

141110

If you are interested in this study or have questions about your child's eligibility, please contact:

Rebecca D. Considine Research Institute, 330-543-3193 or email research@akronchildrens.org

Lead Investigator

Steven Kuerbitz, MD

Director, Divisional Research and Stem Cell Transplantation; Pediatric Hematologist-Oncologist
Showers Family Center for Childhood Cancer and Blood DisordersPediatric Stem Cell Transplant Program

Search our Site

Need Help?

Operator

Ask Children's

For Family & Patients

I am a...

Quicklinks

Find-A-Provider

Find-A-Location

Services

Health Info

About Us

Research

Search our site:

PBTC 039 - Peginterferon Alfa-2b in Treating Younger Patients With Craniopharyngioma That is Recurrent or Cannot Be Removed By Surgery

Peginterferon Alfa-2b in Treating Younger Patients With Craniopharyngioma

Starting Locations:

Legal:

About Akron Children's